Traders Watch List - Medisafe 1 Technologies Corp (OTC: MFTH), Advanced Cell Technology, Inc. (OTC:ACTC), Entest BioMedical Inc. (PINK:ENTB)

Stamford, CT -- (SBWIRE) -- 02/21/2013 -- OTC Stock Picks is engaged in providing the most up to date and useful information on Best Penny Stocks poised to breakout. Our newsletter alerts the market with picks that Wall Street stock traders have ignored or haven’t found out about yet. These are the awesome penny stocks that the ‘underground penny stock experts’ brag about in our penny stock blogs.

Medisafe 1 Technologies Corp (OTC:MFTH) started its trading session with the price $0.0039, and closed at price of $0.0036 by decreasing -2.70%.

MFTH was a gainer in the 5 days activity and jumped about 20%. The one month performance of stock was positive and it scored more than 5.88%.

Should MFTH a Buy or Sell Now? Find Out Here

MFTH’s stocks traded with total volume of 8.27 million shares while the average trading capacity remained 14.13 million shares. Day range of the stock was $0.0032 -$0.0042. Medisafe 1 Technologies Corp., a development stage company, intends to develop a commercial application of the design in a patent titled Protector for administering medicine, which is a device that prevents errors in administering medications.

Advanced Cell Technology, Inc. (OTC:ACTC) stock is at $0.0753, down -2.21 percent from its previous close of $0.08. The stock opened the session at $0.08 and touched its highest price point at $0.08. ACTC stock’s lowest price point for the session stood at $0.08.

Stocks graphical chart shows a bearish trend during its last one month’s trading session. It remained positive with 19.52% during previous three months trade.

Can ACTC Show a Strong Recovery? Find out in This Research Report

Its today’s volume is 7.09 million shares in comparison to its usual trading volume of 13.25 million shares. Its beta value stands at -1.88points. Currently stocks EPS is $-0.02.Advanced Cell Technology, Inc. a leader in the regenerative medicine space, announced that the Company’s chief scientific officer, Robert Lanza, MD, has been appointed editor-in-chief of the scientific journal BioResearch Open Access. The publication’s current editor, Jane Taylor, Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, will continue in her role as Editor.

Entest BioMedical Inc. (PINK:ENTB)stock is at $0.0073, up 7.35 percent from its previous close of $0.01. Its today’s volume is 48.87million shares in comparison to its usual trading volume of 30.56 million shares. The stock opened the session at $0.01 and touched its highest price point at $0.01.
ENTB lowest price point for the session stood at $0.0047, and its 52 week price range stood at $0.0001 - $0.42. The company has total of 446.52 million outstanding shares and its total market capitalization is $3.26 million. Its beta value stands at 43.39 times and earnings per share was $-0.05.

Where ENTB is Headed Exactly? Find out in This Trend Analysis Reports

Previous 5 days graph demonstrated a positive move of 97.3%. ENTB’s quarterly performance remained green with the percentage of 711.11, while its year to date performance showed that the stock advanced overall 563.64%.Entest BioMedical, Inc. engages in the development and commercialization of immunotherapeutic therapies for the veterinary market. The company develops ImenVax family of canine cancer vaccines, which include ImenVax I, a therapeutic for canine cancer, which utilizes the patient’s own tumor cells to induce the immune system to attack the remaining tumor cells; ImenVax II that utilizes cell lines for sustained release of immunologically relevant cytokines for maximum anti-tumor immune responses; and ImenVax III, a canine cancer vaccine to treat tumors through stimulating immune response.

About OTC Stock Picks
The team is among the US market leaders in connecting stocks to investors. With over two decades of market experience, the team prides itself on having the ‘pulse’ of the stock market. The company tracks over 100 different stocks with the goal of bringing investor attention to stock trading opportunities. The team is exceptional at predicting momentum-changes in stocks via technical analysis and fundamentals, and quickly relaying this information through its penny stock newsletter. The company offers investors Free Level II service and Free Real Time Stock Charts on its company website.

Disclaimer
OTC Stock Picks is not a registered securities adviser. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides updates on selected stocks via press releases, newsletters, and company website, but this should not be construed as a recommendation to buy or sell.